Literature DB >> 19720728

tert-Butylphenylacetylene is a potent mechanism-based inactivator of cytochrome P450 2B4: inhibition of cytochrome P450 catalysis by steric hindrance.

Haoming Zhang1, Hsia-lien Lin, Vyvyca J Walker, Djemel Hamdane, Paul F Hollenberg.   

Abstract

We have demonstrated that 4-(tert-butyl)-phenylacetylene (tBPA) is a potent mechanism-based inactivator for cytochrome P450 2B4 (P450 2B4) in the reconstituted system. It inactivates P450 2B4 in a NADPH- and time-dependent manner with a K(I) of 0.44 microM and k(inact) of 0.12 min(-1). The partition ratio was approximately zero, indicating that inactivation occurs without the reactive intermediate leaving the active site. Liquid chromatography-mass spectrometry analyses revealed that tBPA forms a protein adduct with a 1:1 stoichiometry. Peptide mapping of the tBPA-modified protein provides evidence that tBPA is covalently bound to Thr302. This is consistent with results of molecular modeling that show the terminal carbon of the acetylenic group is only 3.65 A away from Thr302. To characterize the effect of covalent modification of Thr302, tBPA-modified P450 2B4 was purified to homogeneity from the reconstituted system. The Soret band of tBPA-modified protein is red-shifted by 5 to 422 nm compared with unmodified protein. Benzphetamine binding to the modified P450 2B4 causes no spin shift, indicating that substrate binding and/or the heme environment has been altered by covalently bound tBPA. Cytochrome P450 reductase reduces the unmodified and tBPA-modified P450s at approximately the same rate. However, addition of benzphetamine stimulates the rate of reduction of unmodified P450 2B4 by approximately 20-fold but only marginally stimulates reduction of the tBPA-modified protein. This large discrepancy in the stimulation of the first electron transfer by benzphetamine strongly suggests that the impairment of P450 catalysis is due to inhibition of benzphetamine binding to the tBPA-modified P450 2B4.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19720728      PMCID: PMC2774989          DOI: 10.1124/mol.109.059808

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  26 in total

1.  A truncation of 2B subfamily cytochromes P450 yields increased expression levels, increased solubility, and decreased aggregation while retaining function.

Authors:  E E Scott; M Spatzenegger; J R Halpert
Journal:  Arch Biochem Biophys       Date:  2001-11-01       Impact factor: 4.013

2.  Determination of the rate of reduction of oxyferrous cytochrome P450 2B4 by 5-deazariboflavin adenine dinucleotide T491V cytochrome P450 reductase.

Authors:  Haoming Zhang; Larry Gruenke; Dave Arscott; Anna Shen; Charles Kasper; Danni L Harris; Michael Glavanovich; Richard Johnson; Lucy Waskell
Journal:  Biochemistry       Date:  2003-10-14       Impact factor: 3.162

3.  Effect of conformational dynamics on substrate recognition and specificity as probed by the introduction of a de novo disulfide bond into cytochrome P450 2B1.

Authors:  Haoming Zhang; Cesar Kenaan; Djemel Hamdane; Gaston Hui Bon Hoa; Paul F Hollenberg
Journal:  J Biol Chem       Date:  2009-07-15       Impact factor: 5.157

4.  Rate-limiting step in the reconstituted microsomal drug hydroxylase system.

Authors:  Y Imai; R Sato; T Iyanagi
Journal:  J Biochem       Date:  1977-11       Impact factor: 3.387

5.  Hydroxylation of camphor by reduced oxy-cytochrome P450cam: mechanistic implications of EPR and ENDOR studies of catalytic intermediates in native and mutant enzymes.

Authors:  R Davydov; T M Makris; V Kofman; D E Werst; S G Sligar; B M Hoffman
Journal:  J Am Chem Soc       Date:  2001-02-21       Impact factor: 15.419

6.  Branchpoint for heme alkylation and metabolite formation in the oxidation of arylacetylenes by cytochrome P-450.

Authors:  P R Ortiz de Montellano; E A Komives
Journal:  J Biol Chem       Date:  1985-03-25       Impact factor: 5.157

7.  Mechanism of oxidation of pi bonds by cytochrome P-450. Electronic requirements of the transition state in the turnover of phenylacetylenes.

Authors:  E A Komives; P R Ortiz de Montellano
Journal:  J Biol Chem       Date:  1987-07-15       Impact factor: 5.157

8.  1-Ethynylpyrene, a suicide inhibitor of cytochrome P-450 dependent benzo[a]pyrene hydroxylase activity in liver microsomes.

Authors:  L S Gan; A L Acebo; W L Alworth
Journal:  Biochemistry       Date:  1984-08-14       Impact factor: 3.162

9.  Kinetics of reduction of purified liver microsomal cytochrome P-450 in the reconstituted enzyme system studied by stopped flow spectrophotometry.

Authors:  K P Vatsis; D D Oprian; M J Coon
Journal:  Acta Biol Med Ger       Date:  1979

10.  Determinants of protein modification versus heme alkylation: inactivation of cytochrome P450 1A1 by 1-ethynylpyrene and phenylacetylene.

Authors:  W K Chan; Z Sui; P R Ortiz de Montellano
Journal:  Chem Res Toxicol       Date:  1993 Jan-Feb       Impact factor: 3.739

View more
  19 in total

1.  Thr302 is the site for the covalent modification of human cytochrome P450 2B6 leading to mechanism-based inactivation by tert-butylphenylacetylene.

Authors:  Hsia-lien Lin; Haoming Zhang; Matthew J Pratt-Hyatt; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2011-09-19       Impact factor: 3.922

2.  Structural analysis of mammalian cytochrome P450 2B4 covalently bound to the mechanism-based inactivator tert-butylphenylacetylene: insight into partial enzymatic activity.

Authors:  Sean C Gay; Haoming Zhang; P Ross Wilderman; Arthur G Roberts; Tong Liu; Sheng Li; Hsia-Lien Lin; Qinghai Zhang; Virgil L Woods; C David Stout; Paul F Hollenberg; James R Halpert
Journal:  Biochemistry       Date:  2011-05-13       Impact factor: 3.162

Review 3.  Acetylenes: cytochrome P450 oxidation and mechanism-based enzyme inactivation.

Authors:  Paul R Ortiz de Montellano
Journal:  Drug Metab Rev       Date:  2019-07-07       Impact factor: 4.518

4.  Identification of the residue in human CYP3A4 that is covalently modified by bergamottin and the reactive intermediate that contributes to the grapefruit juice effect.

Authors:  Hsia-Lien Lin; Cesar Kenaan; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2012-02-16       Impact factor: 3.922

5.  Mechanism-based inactivation of human cytochrome P450 2B6 by clopidogrel: involvement of both covalent modification of cysteinyl residue 475 and loss of heme.

Authors:  Haoming Zhang; Hemali Amunugama; Sarah Ney; Nyemade Cooper; Paul F Hollenberg
Journal:  Mol Pharmacol       Date:  2011-08-23       Impact factor: 4.436

6.  Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex.

Authors:  Haoming Zhang; Chitra Sridar; Cesar Kenaan; Hemali Amunugama; David P Ballou; Paul F Hollenberg
Journal:  J Pharmacol Exp Ther       Date:  2011-06-09       Impact factor: 4.030

7.  Potent mechanism-based inactivation of cytochrome P450 2B4 by 9-ethynylphenanthrene: implications for allosteric modulation of cytochrome P450 catalysis.

Authors:  Haoming Zhang; Sean C Gay; Manish Shah; Maryam Foroozesh; Jiawang Liu; Yoichi Osawa; Qinghai Zhang; C David Stout; James R Halpert; Paul F Hollenberg
Journal:  Biochemistry       Date:  2013-01-04       Impact factor: 3.162

8.  The effect of ritonavir on human CYP2B6 catalytic activity: heme modification contributes to the mechanism-based inactivation of CYP2B6 and CYP3A4 by ritonavir.

Authors:  Hsia-lien Lin; Jaime D'Agostino; Cesar Kenaan; Diane Calinski; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2013-07-25       Impact factor: 3.922

9.  Covalent modification of Thr302 in cytochrome P450 2B1 by the mechanism-based inactivator 4-tert-butylphenylacetylene.

Authors:  Hsia-lien Lin; Haoming Zhang; Monica Jushchyshyn; Paul F Hollenberg
Journal:  J Pharmacol Exp Ther       Date:  2010-03-03       Impact factor: 4.030

10.  Mechanism-based inactivation of cytochrome P450 2B6 by methadone through destruction of prosthetic heme.

Authors:  Hemali T Amunugama; Haoming Zhang; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2012-06-08       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.